Reading Time: 13 minutes
Buprenorphine has treated opioid use disorder since 2002, and it now comes as a daily film or tablet and as a shot given weekly or monthly. This guide covers what it does at the opioid receptor, how a first dose is timed so it does not backfire, what the label warns about, and where to look for a clinician who can prescribe it.
Key Points About Buprenorphine Treatment
- Buprenorphine partly switches on opioid receptors, easing withdrawal and cravings while its effects level off at higher doses.
- Daily films or tablets, alone or paired with naloxone, plus weekly and monthly injections at a clinic are the options.
- The first dose waits for clear withdrawal signs, because starting too soon after fentanyl can set off precipitated withdrawal.
- Alcohol, benzodiazepines and other sedatives can slow breathing dangerously when combined with buprenorphine, the label warns.
- A 2025 AAFP review puts the shortest useful course at a year, and the label sets no maximum length.
In This Article
- What Is Buprenorphine?
- How Does Buprenorphine Work?
- Types of Buprenorphine Medications
- Starting Buprenorphine Treatment
- Is Buprenorphine Safe? Side Effects and Warnings
- Does Buprenorphine Treatment Work?
- Can Buprenorphine Be Misused?
- How Long Do People Take Buprenorphine?
- What Does Buprenorphine Treatment Involve?
- How to Find a Buprenorphine Prescriber
- Does Insurance Cover Buprenorphine?
- Frequently Asked Questions About Buprenorphine
What Is Buprenorphine?
Buprenorphine is a prescription drug that treats opioid use disorder, a condition in which opioid use becomes compulsive and hard to control. It eases withdrawal and reduces cravings, and it is itself an opioid. The Drug Enforcement Administration (DEA) lists it as a partial opioid agonist, meaning it acts on the same receptors as other opioids with less of an effect, and as a Schedule III controlled substance, the middle tier between Schedule II and Schedule IV. Methadone, another medication for opioid use disorder, sits in Schedule II.
The Food and Drug Administration (FDA) approved buprenorphine for opioid use disorder in 2002. Since 2023, any clinician whose DEA registration includes Schedule III may prescribe it, so it turns up in doctors’ offices, through telehealth and at opioid treatment programs. The FDA has also approved buprenorphine in forms made for pain: a patch worn on the skin, a film placed against the cheek and an injection used in hospitals. None of those three treats opioid use disorder. Suboxone pairs buprenorphine with naloxone, a drug that can reverse an opioid overdose.
How Does Buprenorphine Work?
Buprenorphine latches onto the brain’s opioid receptors and switches them on only partway. That partial action quiets withdrawal and cravings, and it keeps other opioids from taking full hold while the medication is in the body.
It is a partial agonist at the mu-opioid receptor, the same receptor heroin, fentanyl and methadone act on. Its opioid effects are “limited by a ceiling effect,” the Suboxone prescribing information says, so they level off rather than climb with each dose. The Drug Enforcement Administration (DEA) adds that it also blocks or reduces the effects of a full agonist opioid taken at the same time.
| Medication type | Example | What it does at opioid receptors | Effect at higher doses |
|---|---|---|---|
| Full agonist | Methadone | Fully activates them | Keeps increasing |
| Partial agonist | Buprenorphine | Partly activates them | Levels off |
| Antagonist | Naltrexone | Blocks them | No opioid effect |
The ceiling does not make the medication risk-free. Buprenorphine can still slow breathing enough to be life-threatening, and the danger grows when it is mixed with benzodiazepines, alcohol or other sedatives, the label warns.
A steady dose rarely produces a high. Dependence on the medication is an expected physical response to regular use rather than the same thing as addiction, and people taking medication for opioid use disorder “are considered to be in recovery,” according to TIP 63 from the Substance Abuse and Mental Health Services Administration (SAMHSA).
Many products pair buprenorphine with naloxone. Under the tongue, only small amounts of naloxone are absorbed, and in that combination the label says it “may deter injection.” That is not the same as Narcan nasal spray, the rescue medicine that reverses an opioid overdose.
A dose usually keeps working for 24 to 36 hours, according to the Centre for Addiction and Mental Health.
Types of Buprenorphine Medications
Buprenorphine is available in two basic forms: something that dissolves in the mouth, either alone or combined with naloxone, and an injection that lasts a week or a month and is given by a clinician. Your prescriber helps pick between them.
| Medication | How it is taken | How often | Where you get it |
|---|---|---|---|
| Buprenorphine and naloxone film (Suboxone and generics) | Under the tongue or inside the cheek | Daily | At home, from a prescriber and a pharmacy |
| Buprenorphine and naloxone tablets (Zubsolv, approved 2013, and generics) | Under the tongue | Daily | At home, from a prescriber and a pharmacy |
| Buprenorphine tablets (generic; once sold as Subutex) | Under the tongue | Daily | At home, from a prescriber and a pharmacy |
| Sublocade (extended-release injection) | Under the skin, by a clinician | Monthly | A clinic certified under the Sublocade REMS |
| Brixadi (extended-release injection) | Under the skin, by a clinician | Weekly or monthly | A healthcare setting certified under the Brixadi REMS |
Neither injection can be taken at home. Each goes under the skin in a clinic or another setting certified under that product’s risk evaluation and mitigation strategy (REMS), a safety program the Food and Drug Administration (FDA) requires, and each carries a boxed warning that it must never go into a vein.
The FDA approved Brixadi on May 23, 2023. The weekly version can follow one dose of a product that dissolves in the mouth; the monthly version is for someone already using buprenorphine. Sublocade is monthly, and Indivior, which makes it, announced on Feb 24, 2025 that its label now allows a start after one such dose as well. Zubsolv, a naloxone tablet brand, was approved in 2013, and the film and the plain buprenorphine tablet also come as generics.
Starting Buprenorphine Treatment
The first dose usually comes once withdrawal is clearly underway. Taken too early after heroin, fentanyl or another full opioid, buprenorphine can trigger precipitated withdrawal, a sudden and intense withdrawal. The Suboxone label tells prescribers to wait for objective, clear signs of withdrawal. A clinician looks for them, often scoring them on a standard scale.
Assessment with a clinician
Waiting for withdrawal signs
First dose and check-in
Finding the right doseFentanyl has made starting treatment more challenging, the American Society of Addiction Medicine (ASAM) said in its 2023 clinical considerations. What raises the risk of precipitated withdrawal varies from person to person, Berk and colleagues reported in JAMA Network Open in 2025. Options are a standard start, a low-dose start that steps the dose up while a person keeps using some opioids, or a high-dose start in hospital. Evidence on low-dose starts is still emerging, mostly from hospitals. Ask your prescriber which approach fits you.
If precipitated withdrawal does happen, the prescriber is the first call. ASAM’s preferred response is more buprenorphine under a clinician’s direction, with treatment continuing afterward.
Starts happen in a prescriber’s office, by telehealth, in an emergency department, an opioid treatment program, or within detox, intensive outpatient (IOP), partial hospitalization (PHP) or inpatient rehab. After that comes stabilization, finding the dose that holds withdrawal and cravings in check, and maintenance with regular check-ins, the label and the UAMS model say.
Is Buprenorphine Safe? Side Effects and Warnings
Buprenorphine is FDA-approved for opioid use disorder and widely prescribed, and the FDA judges its benefits to clearly outweigh its risks. Safe is not the same as free of effects: some reactions are uncomfortable and pass, and alcohol, benzodiazepines or another sedative can slow breathing to a dangerous level.
Breathing problems
Alcohol and sedatives
Store securely
Liver warning signs
Dental care
PregnancyMost everyday complaints come from the forms that dissolve in the mouth. The Suboxone prescribing information lists numbness, redness or pain there, headache, nausea, vomiting, sweating, constipation and trouble sleeping. If one does not let up, tell your prescriber.
The serious warnings start with breathing: if breathing becomes slow or shallow, call 911. A child who swallows the medication is in the most danger: the label warns that this can severely depress a child’s breathing, sometimes fatally, so store it out of reach.
Benzodiazepines, other sedatives and alcohol raise the risk of overdose and death. Even so, the FDA said in 2017 that treatment should not be withheld from someone who also takes a benzodiazepine, provided the mix is managed carefully. A 2025 review from the American Academy of Family Physicians (AAFP) agrees.
The same label names liver signs to watch for: dark urine, light stools, yellowing of the skin or eyes, and stomach pain.
In 2022 the FDA warned that tooth decay and tooth loss had been reported with the dissolving products. Once the medicine has dissolved, rinse with a sip of water, swish it around, swallow, and hold off brushing for at least an hour. Tell your dentist.
In 2025 the Centers for Disease Control and Prevention (CDC) said that “Methadone and buprenorphine are recommended medications” for opioid use disorder during pregnancy, that stopping opioids quickly then “is not recommended”, and that neonatal opioid withdrawal syndrome (NOWS), withdrawal in a newborn, is “expected and treatable”.
Does Buprenorphine Treatment Work?
Yes. Buprenorphine lowers the chance that someone dies of an opioid overdose, and it helps people remain in treatment.
Among people who survived a nonfatal overdose, those given buprenorphine had a 38% lower chance of dying of an opioid overdose than people who did not receive it, according to a 2018 study by Larochelle and colleagues. That figure compares groups, so it is not a guarantee for any one person.
In a 2025 review, the American Academy of Family Physicians (AAFP) found that people who finish a full year of treatment relapse less often after stopping.
Reach is the weak link. The Substance Abuse and Mental Health Services Administration (SAMHSA) reports in the National Survey on Drug Use and Health for 2025 that 15.7% of people aged 12 and older with an opioid use disorder got medication for it, called MOUD. That is 623,000 people.
Can Buprenorphine Be Misused?
Yes, it can be. Buprenorphine is an opioid, and misuse means taking it without a prescription or against a prescriber’s direction. People not dependent on opioids feel its effects most.
Most people who use it without a prescription are not chasing a high. In a 2018 research report, the National Institute on Drug Abuse described two surveys of illicit use: 97% of people said they took it to head off cravings, and 90% to head off withdrawal.
Han and colleagues reported in JAMA Network Open in 2021, using survey data from 2015 to 2019, that nearly three-fourths of adults who used buprenorphine in the past year did not misuse it.
The risk is lower than with full opioid agonists. Buprenorphine produces a ceiling effect, so its opioid effects level off as the dose rises instead of climbing with it. The DEA places it in Schedule III. Combination products also carry naloxone, which SAMHSA says may deter injection.
The signs of buprenorphine misuse are easy to overlook in someone with a prescription.
800-681-1058
Sponsored
How Long Do People Take Buprenorphine?
There is no set end date. The prescribing information for Suboxone lists no maximum duration for maintenance treatment, and it notes that “Patients may require treatment indefinitely.”
A 2025 review from the American Academy of Family Physicians (AAFP) puts the shortest useful course at a year and says staying on it longer makes sense while it is still helping. A 2026 review by Castro and colleagues describes tapers as slow and adjusted to the person. Stopping is a decision to work out with the prescriber rather than a date on a calendar.
Leaving treatment carries its own risk. The National Institute on Drug Abuse (NIDA) reported “high relapse rates among patients tapered off” buprenorphine in a 2018 research report. Tolerance to opioids also falls during a break, so a dose that was manageable before can cause an overdose. Naloxone reverses an opioid overdose, and the nasal spray is sold over the counter, so having it nearby matters most in the weeks after a taper.
What Does Buprenorphine Treatment Involve?
Buprenorphine treatment is mostly the medication, refilled on a schedule and checked with drug testing now and then. Prescriber visits review withdrawal, cravings and side effects, and screening for hepatitis, HIV and other health needs often comes up too.
Support is offered and tends to help, but counseling is not a condition of getting the medication. A 2025 review from the American Academy of Family Physicians (AAFP) advises against tying the two together, as does the federal rule for opioid treatment programs revised in 2024. Options include individual, group or family counseling, peer support and mutual-help groups.
Care happens in a primary care office or addiction medicine practice, by telehealth, at an opioid treatment program, or alongside outpatient rehab, intensive outpatient (IOP), partial hospitalization (PHP) or inpatient treatment. Buprenorphine is one of the medications in medication-assisted treatment, often called MAT.
How to Find a Buprenorphine Prescriber
No special certification is needed any more. A prescriber needs a DEA registration that includes Schedule III, and state law decides the rest: visits can happen in an office or through telehealth.
The X-waiver is gone: the Consolidated Appropriations Act of 2023 ended it, and the DEA confirmed the change in a Jan 12, 2023 letter. Since June 27, 2023, the MATE Act has required DEA registrants to train in treating opioid use disorder, part of the wider federal rule changes for medication-assisted treatment.
The DEA’s telemedicine rule, in force since Dec 31, 2025, caps a remote start at six months: audio-video or audio-only, with the state prescription drug monitoring program checked first, then another telemedicine pathway or a visit in person. Wider flexibilities last through Dec 31, 2026, and opioid treatment programs can begin buprenorphine by telehealth too.
Some emergency departments start treatment as well. FindTreatment.gov searches by ZIP code, the treatment centers by state and city directory lists programs by place, and the SAMHSA OTP Directory names opioid treatment programs.
State laws still vary, so some states ask more of prescribers than others.
Primary care or addiction medicine
Telehealth prescriber
Opioid treatment program
Treatment program or rehabDoes Insurance Cover Buprenorphine?
Medicaid must cover buprenorphine in every state, Medicare covers it through Part B while Part D may cover it, and most private plans include it, sometimes after prior authorization.
Medicaid
Medicare
Private insurance
Free or low-costMedicaid’s obligation is permanent: the Centers for Medicare & Medicaid Services (CMS) told state Medicaid directors that every state must cover medications for opioid use disorder, buprenorphine among them. What Medicaid rehab coverage includes, and what it costs, varies by state.
Medicare.gov says Part B covers it in a clinician’s office or an enrolled opioid treatment program, with no copayment there, though the Part B deductible applies. A pharmacy prescription falls to Part D, which may cover it, and Medicare rehab coverage splits the same way.
Marketplace plans must cover substance use disorder treatment as an essential health benefit, HealthCare.gov says, and federal parity rules apply to whatever mental health and substance use benefits a plan offers, CMS explains. Injections are usually billed differently from a pharmacy prescription, so check the rehab insurance drug list.
Frequently Asked Questions About Buprenorphine
Yes. Buprenorphine is an opioid, and the DEA classes it as a partial opioid agonist: it switches on the brain’s opioid receptors only partway. Federal law places it in Schedule III, the tier of controlled substances that sits between Schedule II and Schedule IV. For someone with opioid tolerance, a steady dose mostly brings relief from withdrawal and cravings rather than a high, though the opioid risks do not disappear.
No. Suboxone is a brand that pairs buprenorphine with naloxone, and it is one product among several. Buprenorphine is the medication that treats opioid use disorder, and Suboxone is a name for one combination of it. Generic films and tablets carry the same two drugs, and some products contain buprenorphine alone.
Often, yes, because the first dose is usually held until withdrawal is clearly underway. Starting sooner, while a full opioid such as fentanyl is still active, risks precipitated withdrawal, which arrives fast and hard. Once the medication takes hold, it eases the withdrawal that prompted the dose.
Yes. Federal telemedicine rules allow a start without an in-person visit, by video or in some cases by audio alone, and opioid treatment programs can begin buprenorphine remotely. The prescriber still checks the state prescription drug monitoring program first, and state law can add requirements of its own.
The combination is risky, because alcohol and benzodiazepines both slow breathing and buprenorphine adds to that effect. Tell your prescriber about every medication you take, including sedatives and sleep aids, so the mix can be watched. Do not stop a benzodiazepine or alcohol suddenly without medical advice, since abrupt withdrawal can be dangerous for someone who takes a benzodiazepine daily or drinks heavily.
Yes. The ceiling effect makes an overdose less likely than with a full opioid for someone with tolerance, but it does not rule one out. Other depressants raise the danger, and so does little or no opioid tolerance, which is why a swallowed dose is especially dangerous for a child. Naloxone reverses an opioid overdose, so keep it on hand.
Both are extended-release buprenorphine injections that a clinician gives under a REMS. Sublocade is dosed once a month. Brixadi comes in a weekly form and a monthly form.
Often, yes, and Medicare splits the bill between two parts. Part B covers a dose given in a clinician’s office, or at an opioid treatment program that takes Medicare. A prescription filled at a pharmacy goes to Part D instead, where coverage is possible and the plan’s drug list decides.
Featured Rehab Centers
Finding facilities near you…
